Target intelligence / Profile preview

mRNA cap 2'-O-methyltransferase (J3R) (J3R)

Target
J3R
Molecular classification
Enzyme, Methyltransferase, S-adenosyl-L-methionine-dependent methyltransferase, RNA-binding protein
01

Overview

The J3R protein, also known as VP39, is a critical enzyme in the Mpox virus (MPXV) life cycle, functioning primarily as an mRNA cap 2'-O-methyltransferase. It is responsible for modifying the 5' cap of viral mRNA by transferring a methyl group from S-adenosyl-L-methionine (SAM) to the ribose 2'-O position of the first transcribed nucleotide. This modification is essential for the virus to mimic host mRNA, thereby evading detection by the host's innate immune sensors such as IFIT proteins and MDA5, which normally recognize unmethylated 'non-self' RNA. Beyond its methyltransferase activity, J3R also acts as a processivity factor for the viral poly(A) polymerase, ensuring the production of long poly(A) tails required for mRNA stability and translation. Due to its indispensable role in viral replication and immune suppression, J3R is considered a high-priority target for the development of novel anti-poxvirus therapeutics. Current research focuses on small-molecule inhibitors that occupy the SAM-binding pocket or the RNA-binding groove to block its enzymatic activity.

Other names
VP392'-O-methyltransferase VP39Poly(A) polymerase small subunitCap-specific mRNA (nucleoside-2'-O-)-methyltransferaseMPXV_gp115
02

Mechanism of action

Inhibition of the methyltransferase catalytic site prevents the 2'-O-methylation of the viral mRNA cap structure, leading to the recognition of viral RNA by host sensors like MDA5 and IFIT, thereby triggering an interferon-mediated immune response and inhibiting viral protein synthesis.

03

Biological functions

mRNA capping2'-O-methylation of viral mRNAPolyadenylation processivityViral replicationImmune evasion
04

Disease associations

Infection (Mpox virus)Viral pathogenesis
05

Safety considerations

Potential cross-reactivity with host methyltransferasesHigh conservation among orthopoxviruses may lead to broad-spectrum activity but requires high specificity to avoid host toxicityEmergence of resistance mutations in the catalytic pocket
06

Interacting drugs

S-adenosyl-L-homocysteine (SAH) analogs

3 more in the full profile.

07

Biomarkers

Viral load (MPXV DNA)Interferon-stimulated gene (ISG) expression levels

Beyond the preview

Go deeper on mRNA cap 2'-O-methyltransferase (J3R) (J3R).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA cap 2'-O-methyltransferase (J3R) (J3R).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call